Next Article in Journal
Identifying Cancer Driver Genes Using Replication-Incompetent Retroviral Vectors
Next Article in Special Issue
A Comparison of Singlet Oxygen Explicit Dosimetry (SOED) and Singlet Oxygen Luminescence Dosimetry (SOLD) for Photofrin-Mediated Photodynamic Therapy
Previous Article in Journal
The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy
Previous Article in Special Issue
Modulation of the Anti-Tumor Efficacy of Photodynamic Therapy by Nitric Oxide

Photodynamic Therapy and Non-Melanoma Skin Cancer

Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester M6 8HD, UK
Author to whom correspondence should be addressed.
Academic Editor: Michael R. Hamblin
Cancers 2016, 8(10), 98;
Received: 11 July 2016 / Revised: 15 October 2016 / Accepted: 18 October 2016 / Published: 22 October 2016
(This article belongs to the Special Issue Photodynamic Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common malignancy among the Caucasian population. Photodynamic therapy (PDT) is gaining popularity for the treatment of basal cell carcinoma (BCC), Bowen’s disease (BD) and actinic keratosis (AK). A topical or systemic exogenous photosensitiser, results in selective uptake by malignant cells. Protoporphyrin IX (PpIX) is produced then activated by the introduction of a light source. Daylight-mediated MAL (methyl aminolaevulinate) PDT for AKs has the advantage of decreased pain and better patient tolerance. PDT is an effective treatment for superficial BCC, BD and both individual and field treatment of AKs. Excellent cosmesis can be achieved with high patient satisfaction. Variable results have been reported for nodular BCC, with improved outcomes following pretreatment and repeated PDT cycles. The more aggressive basisquamous, morphoeic infiltrating subtypes of BCC and invasive squamous cell carcinoma (SCC) are not suitable for PDT. Prevention of “field cancerization” in organ transplant recipients on long-term immunosuppression and patients with Gorlin syndrome (naevoid basal cell carcinoma syndrome) is a promising development. The optimisation of PDT techniques with improved photosensitiser delivery to target tissues, new generation photosensitisers and novel light sources may expand the future role of PDT in NMSC management. View Full-Text
Keywords: photodynamic therapy; non-melanoma skin cancer; basal cell carcinoma; actinic keratosis; field cancerization; organ transplant recipients; Gorlin syndrome photodynamic therapy; non-melanoma skin cancer; basal cell carcinoma; actinic keratosis; field cancerization; organ transplant recipients; Gorlin syndrome
Show Figures

Figure 1

MDPI and ACS Style

Griffin, L.L.; Lear, J.T. Photodynamic Therapy and Non-Melanoma Skin Cancer. Cancers 2016, 8, 98.

AMA Style

Griffin LL, Lear JT. Photodynamic Therapy and Non-Melanoma Skin Cancer. Cancers. 2016; 8(10):98.

Chicago/Turabian Style

Griffin, Liezel L.; Lear, John T. 2016. "Photodynamic Therapy and Non-Melanoma Skin Cancer" Cancers 8, no. 10: 98.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop